The Federal Circuit Weighs in On Hatch-Waxman “Skinny” Label Infringement Dispute

The Hatch-Waxman Act allows a generic drugmaker to rely on a branded drugmaker’s Food and Drug Administration-approved New Drug Application if the generic drugmaker can show that the generic drug has the same active ingredient and is bioequivalent to the branded drug……
By: Fish & Richardson